OTCMKTS:CRXLY - Crucell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Crucell NV is a Netherlands-based biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. The Company's product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. It focuses on the paediatric, travel and endemic, and respiratory fields. Its core product portfolio includes Quinvaxem, a liquid pentavalent vaccine against five important childhood diseases; Hepavax-Gene, a hepatitis B vaccine; Epaxal, an aluminum-free hepatitis A vaccine; Vivotif and Dukoral, oral vaccines against typhoid and cholera; and Inflexal V, a virosomal adjuvanted vaccine against influenza. It has offices in the Netherlands, China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States and Vietnam.

Receive CRXLY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRXLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:CRXLY
CUSIPN/A
WebN/A
Phone+31-71-5199100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Crucell (OTCMKTS:CRXLY) Frequently Asked Questions

What is Crucell's stock symbol?

Crucell trades on the OTCMKTS under the ticker symbol "CRXLY."

Has Crucell been receiving favorable news coverage?

News articles about CRXLY stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crucell earned a news and rumor sentiment score of 0.13 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Crucell.

How do I buy shares of Crucell?

Shares of CRXLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Crucell?

Crucell's mailing address is Archimedesweg 4, LEIDEN, 2333CN, Netherlands. The biopharmaceutical company can be reached via phone at +31-71-5199100.


MarketBeat Community Rating for Crucell (OTCMKTS CRXLY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about Crucell and other stocks. Vote "Outperform" if you believe CRXLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRXLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.